Taking the guesswork out of infectious diseases
We are advancing infectious disease diagnostics for patients managing challenging infections.
Trusted by leading institutions
Our diagnostic and software products
BIOTIA‑ID Urine Test
Metagenomic detection of 44+ urogenital pathogens and a comprehensive AMR panel from a single urine sample. Accessible to patients via our telehealth partner.
Learn moreBIOTIA‑ID Joint Fluid Test
Metagenomic detection of pathogens and resistance markers in synovial fluid for native and prosthetic joint infections.
Learn moreBIOTIA-DX
Isolate identification and outbreak detection for hospitals and labs — turning routine sequencing into actionable infection control intelligence.
View case studiesGeoSeeq
Cloud platform for genomic surveillance and microbiome research at scale, used by over 100 organizations across 100 countries.
Visit GeoSeeq
Powered by clinical metagenomics
Biotia is a leader in clinical metagenomic-based infectious disease diagnostics, a more advanced method of next-generation sequencing for comprehensive, pathogen-agnostic detection.
BIOTIA-ID | NGS Competitors | Standard care | |
|---|---|---|---|
| Test type | Clinical metagenomics | 16s sequencing | Culture |
| Results turnaround | 2–3 business days | 2–5 business days | 2–5 business days |
| Price | $249 | $259 | Varies |
| Resolution & detail | Detailed – Species or strain level resolution | Poor – Genus or species, with some groups unresolved | Detailed – Genus or species for species that grow |
| Kinds of microbes | Extensive – Bacteria, fungi, anaerobes, fastidious, and atypical pathogens | Limited – Bacteria only | Limited – Common bacteria and fungi only |
| Accuracy | High – limited contamination & false positives | Low – High potential for contamination & false positives | Low – High potential for contamination & false negatives |
| % of genome considered | Extensive – thousands of genes across the entire genome | Low – Looks at only one gene in a section of the genome | None, not applicable |
| Future biomarker and therapeutic insights | High | Low | None |
| Antimicrobial resistance prediction | High – Clinically-validated resistance reporting | None | Separate testing required |
| Clinical relevance | High – Healthy microbes filtered from report | Low – Reports non-pathogenic species | Low – Misses pathogenic species |
Latest from Biotia
Read the blog, written by the Biotia team and our collaborators to help patients better understand UTI prevention, diagnostic, and treatment options.
Biotia
Biotia is a health tech company advancing infectious disease diagnostics for challenging infections. We pair clinical metagenomics and artificial intelligence to develop diagnostic and software solutions to help patients, providers, and health systems respond to infectious disease threats.
